Spero Therapeutics, Inc.
SPRONasdaq
$1.58
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↓ -36.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$90.5M
Enterprise Value
$34.4M
P/E
5.9
P/S
1.5
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$61.2M
Net Income (TTM)
$15.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
22.1%
Net Margin
24.9%
ROE
28.8%
ROIC
—
Debt / Equity
—
Net Cash
$56.1M
Return 1Y
-36.3%
Company profile
Spero Therapeutics, Inc. focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
- CEO
- Ankit A. Mahadevia
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 150
- Headquarters
- Massachusetts
- Website
- sperotherapeutics.com
Management & directors
- Rajavelu EstherSee Remarks
- Keutzer TimothyChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
SPRO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$258,000.00↓ -95.6%
Diluted EPS-$0.13↓ -48.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.3M | $18.3M | $53.5M | $103.8M | $48.0M | $66.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$79.1M | -$88.0M | -$42.2M | $21.5M | -$73.4M | $6.3M |
| Net income | -$78.3M | -$89.8M | — | $22.8M | -$68.6M | $8.6M |
| Diluted EPS | — | -$2.91 | -$1.23 | $0.43 | -$1.27 | $0.15 |
| Operating cash flow | -$85.9M | -$64.3M | -$7.7M | -$33.0M | -$23.4M | -$12.6M |
| Free cash flow | -$86.0M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -847.9% | -481.9% | -78.9% | 20.7% | -152.9% | 9.5% |
| Net margin | -839.2% | -491.9% | — | 22.0% | -142.9% | 12.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2M | $13.5M | $15.0M | $5.9M | $14.2M | $5.4M | $41.3M | $258,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$19.1M | -$18.6M | -$21.7M | -$14.7M | -$2.4M | -$7.9M | $31.4M | -$7.5M |
| Net income | -$17.9M | -$17.1M | -$20.9M | -$13.9M | -$1.7M | -$7.4M | $31.5M | -$7.2M |
| Diluted EPS | -$0.33 | -$0.32 | -$0.38 | -$0.25 | -$0.03 | -$0.13 | $0.56 | -$0.13 |
| Operating cash flow | -$18.7M | $12.8M | -$23.4M | -$4.0M | -$17.7M | $17.4M | -$8.4M | $15.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -186.9% | -138.0% | -144.4% | -250.8% | -17.2% | -145.5% | 76.0% | -2921.7% |
| Net margin | -175.2% | -127.3% | -138.8% | -236.1% | -12.0% | -135.6% | 76.3% | -2791.9% |
Company news
Jul 15, 2026
Jul 14, 2026
- 6d agoSpero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO)investorshub.advfn.com
- 6d agoSpero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royaltiesfinance.yahoo.com
- 6d agoInnovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibodyfinance.yahoo.com
- 6d agoSpero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibodyfinance.yahoo.com
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-23 | Deshpande Milind | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-23 | Tregoning Kathleen | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-23 | Smith Cynthia | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-23 | VINK PATRICK V.J.J. | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-23 | THOMAS FRANK E | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-23 | Jackson Scott Thomas | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-23 | Pottage John C Jr | Award | 10,000 | $0.00 | $0.00 | filing |
| 2026-05-04 | Rajavelu Esther· See Remarks | Sale | 25,240 | $2.51 | $63,352.40 | filing |
| 2026-02-06 | Rajavelu Esther· See Remarks | Sale | 50,816 | $2.36 | $119,925.76 | filing |
| 2026-02-06 | Rajavelu Esther· See Remarks | Sale | 37,101 | $2.36 | $87,558.36 | filing |
| 2026-02-06 | Keutzer Timothy· Chief Operating Officer | Sale | 18,652 | $2.36 | $44,018.72 | filing |
| 2026-02-04 | Keutzer Timothy· Chief Operating Officer | Sale | 3,471 | $2.24 | $7,775.04 | filing |
| 2026-02-03 | Keutzer Timothy· Chief Operating Officer | Sale | 24,224 | $2.14 | $51,839.36 | filing |
| 2026-02-02 | Keutzer Timothy· Chief Operating Officer | Sale | 18,891 | $2.20 | $41,560.20 | filing |
| 2026-02-02 | Rajavelu Esther· See Remarks | Sale | 18,442 | $2.20 | $40,572.40 | filing |
| 2026-02-02 | Rajavelu Esther· See Remarks | Award | 249,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Keutzer Timothy· Chief Operating Officer | Award | 68,000 | $0.00 | $0.00 | filing |
| 2025-11-07 | Rajavelu Esther· See Remarks | Sale | 40,270 | $2.37 | $95,439.90 | filing |
| 2025-08-28 | Mahadevia Ankit | Sale | 6,572 | $1.97 | $12,946.84 | filing |
| 2025-08-28 | Keutzer Timothy· Chief Operating Officer | Sale | 1,695 | $1.97 | $3,339.15 | filing |
Latest 20 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.